283 related articles for article (PubMed ID: 35462344)
1. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
[TBL] [Abstract][Full Text] [Related]
2. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
3. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
[TBL] [Abstract][Full Text] [Related]
6. Platinum chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
[TBL] [Abstract][Full Text] [Related]
7. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
[TBL] [Abstract][Full Text] [Related]
8. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
[TBL] [Abstract][Full Text] [Related]
9. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
12. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
[TBL] [Abstract][Full Text] [Related]
14. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Sharma P; Kimler BF; O'Dea A; Nye L; Wang YY; Yoder R; Staley JM; Prochaska L; Wagner J; Amin AL; Larson K; Balanoff C; Elia M; Crane G; Madhusudhana S; Hoffmann M; Sheehan M; Rodriguez R; Finke K; Shah R; Satelli D; Shrestha A; Beck L; McKittrick R; Pluenneke R; Raja V; Beeki V; Corum L; Heldstab J; LaFaver S; Prager M; Phadnis M; Mudaranthakam DP; Jensen RA; Godwin AK; Salgado R; Mehta K; Khan Q
Clin Cancer Res; 2021 Feb; 27(4):975-982. PubMed ID: 33208340
[TBL] [Abstract][Full Text] [Related]
17. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
Xiu M; Zhang P; Wang X; Fan Y; Li Q; Li Q; Wang J; Dong L; Luo Y; Yuan P; Ma F; Xu B
Int J Cancer; 2022 Aug; 151(4):578-589. PubMed ID: 35403702
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
20. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
